

# GOPEN ACCESS

**Citation:** Soliman SSM, Alhamidi TB, Abdin S, Almehdi AM, Semreen MH, Alhumaidi RB, et al. (2020) Effective targeting of breast cancer cells (MCF7) via novel biogenic synthesis of gold nanoparticles using cancer-derived metabolites. PLoS ONE 15(10): e0240156. https://doi.org/ 10.1371/journal.pone.0240156

Editor: Amitava Mukherjee, VIT University, INDIA

Received: June 25, 2020

Accepted: September 17, 2020

Published: October 6, 2020

**Copyright:** © 2020 Soliman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the manuscript.

**Funding:** This study was supported by funds from the University of Sharjah to SSMS and partially by Aljalila Foundation (grant number AJF201777) to Mohamed Haider. No additional external funding was received for this study.

**Competing interests:** The authors have declared that no competing interests exist.

**RESEARCH ARTICLE** 

# Effective targeting of breast cancer cells (MCF7) via novel biogenic synthesis of gold nanoparticles using cancer-derived metabolites

Sameh S. M. Soliman<sup>1,2,3</sup>\*, Tasneem B. Alhamidi<sup>1</sup>, Shifaa Abdin<sup>1</sup>, Ahmed M. Almehdi<sup>4</sup>, Mohammad H. Semreen<sup>1,2</sup>, Razan B. Alhumaidi<sup>1,2</sup>, Sarra B. Shakartalla<sup>1</sup>, Mohamed Haider<sup>1,5,6</sup>, Mohamed I. Husseiny<sup>3,7</sup>, Hany A. Omar<sup>1,8,9</sup>

 Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE, 2 Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, UAE, 3 Faculty of Pharmacy, Zagazig University, Zagazig, Egypt, 4 Department of Chemistry, College of Sciences, University of Sharjah, Sharjah, UAE, 5 Department of Pharmaceutics and Pharmaceutical Technology, College of Sciences, University of Sharjah, Sharjah, UAE, 6 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt, 7 Department of Translational Research & Cellular Therapeutics, Beckman Research Institute of City of Hope, Duarte, CA, United States of America, 8 Department of Pharmacy Practice and Pharmacotherapeutics, College of Sciences, University of Sharjah, Sharjah, UAE,
Department of Pharmacology, Faculty of Pharmacy, Beni-Suef University, Beni Suef, Egypt

\* ssoliman@sharjah.ac.ae

# Abstract

Biogenic synthesis of nanoparticles provides many advantages over synthetic nanoparticles including clean and non-toxic approaches. Nanoparticle-based application for the development of diagnostics and therapeutics is a promising field that requires further enrichment and investigation. The use of biological systems for the generation of gold nanoparticles (AuNPs) has been extensively studied. The search for a biocompatibility approach for the development of nanoparticles is of great interest since it can provide more targeting and less toxicity. Here, we reported a bio-reductive approach of gold to AuNPs using metabolites extracted from mammalian cells, which provided a simple and efficient way for the synthesis of nanomaterials. AuNPs were more efficiently synthesized by the metabolites extracted from breast cancer (MCF7) and normal fibroblasts (F180) cells when compared to metabolites extracted from cell-free supernatants. The metabolites involved in biogenic synthesis are mainly alcohols and acids. Spectroscopic characterization using UV-visible spectra, morphological characterization using electron microscopy and structural characterization using X-ray diffraction (XRD) confirmed the AuNPs synthesis from mammalian cells metabolites. AuNPs generated from MCF7 cells metabolites showed significant anticancer activities against MCF7 and low toxicity when compared to those generated from F180 cells metabolites. The results reflected the cytotoxic activities of the parent metabolites extracted from MCF7 versus those extracted from F180. Comparative metabolomics analysis indicated that MCF7-generated AuNPs harbored tetratetracontane, octacosane, and cyclotetradecane while those generated from F180 harbored a high percentage of stearic, palmitic, heptadecanoic acid. We related the variation in cytotoxic activities between cell types to the

Abbreviations: AuNP, gold nanoparticle; CE, cell extract; F180, normal fibroblast cells; MCF7, breast cancer cells; NE, nanoparticle extract; NP, nanoparticle; SE, supernatant extract; SEM, scanning electron microscopy; SNE, supernatant collected from NP; TEM, transmission electron microscopy. differences in AuNPs-harboring metabolites. The process used in this study to develop the nanoparticles is novel and should have useful future anticancer applications mainly because of proper specific targeting to cancer cells.

# Introduction

Nanotechnology gains lots of interest particularly those employing the use of AuNPs in medical applications. AuNPs showed remarkable potential in diagnostic and therapeutic purposes, including biosensor applications, targeted delivery of anticancer drugs, bio-imaging of cells and tissues, and immunoassays [1]. AuNPs showed superior preference in medical applications when compared to other metal nanoparticles, particularly because of low toxicity [2].

Reduction of Au<sup>3+</sup> ions to AuNPs by biological systems offers clean, nontoxic and ecofriendly synthetic technology [3]. Control synthesis of biocompatible metal nanoparticles using yeast, fungi, bacteria and plants [4, 5], encourage the use of mammalian cells to develop nanoparticles. It has been reported that AuNPs can be generated in situ after incubation of Au<sup>3+</sup> with mammalian cell cultures [6]. Furthermore, it has been observed that nanoparticles can be generated inside the epithelial cells and in intact tumor tissues [6].

The potential toxic impact of AuNPs is controversial, although recent data indicated that cytotoxicity of AuNPs depends on the type of the cell [7] as well as the size and level of aggregation of those nanoparticles [8]. In order to avoid toxicity of NPs and for proper targeting, scientists have employed the use of biological ligands such as proteins, polysaccharides, aptamers, peptides, and small molecules to develop NPs with specific capping [9]. However the use of biological ligands from cancer cells to target its own has never been studied. Therefore, we assumed that generation of AuNPs using mammalian cell metabolites may offer new insight in cancer therapy, since metabolites are the end products of all biological aggregation of the AuNPs with unique capping metabolites that allow variable cytotoxic activities between cell types. The use of cancer cell metabolites to develop NPs as anticancer agents for possible targeting is novel and has never been employed.

# Materials and methods

#### Mammalian cell lines

The cells used in this study included breast cancer cells (MCF7, American Type Culture Collection, Virginia, USA) and normal fibroblast cells (F180, kindly provided by Dr. Ekkehard Dikomey, University Cancer Center, Hamburg University, Hamburg, Germany). The cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) media supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub> under effective aseptic techniques to prevent any possible contamination and according to [10]. The cells were checked every day for confluency and mycoplasma contamination. The positive cultures were immediately discarded and followed by full decontamination of the laboratory.

#### Mammalian cells preparation and metabolites extraction

Mammalian cell cultures were maintained in DMEM media supplemented with 10% FBS and incubated at 37 °C in a humidified atmosphere containing 5%  $CO_2$  in T-75 Corning cell culture flasks with vent cap (Sigma) until confluency. The cultures were then centrifuged at 19000 RCF for 15 min in order to separate the cultures into cells and cell-free supernatants fractions.

The supernatants were collected and extracted by 100% ethyl acetate (2 times), while the cells ( $\sim$ 4x 10<sup>6</sup>) were ground with a pestle and extracted with 100% methanol (1 time). Both extracts were filtered using filter paper and the organic solvents were separated and evaporated using a rotatory evaporator at 45 °C [11]. On the other hand, the metabolites capped the formed gold nanoparticles were extracted by sonicating the NPs with methanol for 15 min at room temperature. The solutions were filtered and the methanol was evaporated. The obtained metabolites residues were either analysed by GC-MS or tested on mammalian cells. All metabolite extracts were described in Table 1.

## Synthesis of AuNPs

Gold chloride solution (1mM) was prepared in phosphate-buffered saline (PBS). The metabolite extract (400 $\mu$ g) was suspended in 1 mL PBS solution, filtered through 0.2 $\mu$ m filters and mixed with 100  $\mu$ L gold chloride solution. The mixture was incubated in 12-well corning plate for 6 days in 37°C. Control experiments were maintained using gold chloride solution in PBS or metabolites extract in PBS without gold chloride. The endpoint was identified when the solution turned in color most likely to purple [12]. In order to collect the nanoparticles, the plates were shaken for 5 min and then decanted in Eppendorf tubes. The tubes were centrifuged at 19000 RCF for 30 min and the supernatant was decanted to a new Eppendorf tube. The collected nanoparticles were further washed with PBS, followed by centrifugation and the nanoparticles were collected and named "AuNPs". The gold nanoparticles (AuNPs) were stored at concentration 50  $\mu$ g/ mL in fresh PBS at 4°C for a period of 4 months.

### Characterization of AuNPs

The synthesized AuNPs were identified using UV/visible spectroscopy by measuring the absorbance of gold at 200–900-nm wavelength range using UV-Vis spectrophotometer (Spectro UV-2510TS; Labomed, Inc.). The shape and surface topology of AuNPs were examined by scanning electron microscope (SEM) using TESCAN VEGA4 XM SEM (SE Detector, 30 kV, high vacuum) and transmission electron microscopy (TEM) using JEOL-@2100, JeolLtd, Japan. The samples were placed on standard carbon-coated copper grids (200-mesh) and airdried for about 2h prior to TEM measurement. The energy-dispersive X-ray spectroscopy (Oxford Instruments X-Max 50 EDS detector) was carried out according to Al-Nuairi et al. [13]. X-ray diffraction (XRD) measurements were carried out using Cu radiation on a Bruker D8 Advance Powder Diffractometer.

The average particle size (z-ave) and size distribution of the synthesized AuNPs were determined by photon correlation spectroscopy at a scattering angle of 90°. Surface charge was measured following principles of laser Doppler velocimetry and phase analysis light scattering

Extract symbol	Description
SE1	Ethyl acetate extract of the supernatant collected from fibroblasts cell cultures
SE2	Ethyl acetate extract of the supernatant collected from MCF7 cell cultures
CE1	Methanol extract of fibroblasts cells
CE2	Methanol extract of MCF7 cells
SNE1	Ethyl acetate extract of the supernatant collected from fibroblasts cell-generated AuNPs
SNE2	Ethyl acetate extract of the supernatant collected from MCF7 cell-generated AuNPs
NE1	Methanol extract of fibroblast cells-generated AuNPs
NE2	Methanol extract of MCF7 cells-generated AuNPs

Table 1. Descriptions of the metabolites extracts employed in the study.

https://doi.org/10.1371/journal.pone.0240156.t001

(M3-PALStechnique). Measurements were carried out on samples after 10x dilution with milliQ deionized water at room temperature using Zetasizer Nano ZS (Malvern Instrument, UK) and according to our protocol [14].

# Cell cytotoxicity using MTT staining

The cell cytotoxicity was performed using 3-(4, 5-dimethyl thiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay as described in [15]. Briefly, 96-well micro-plates were seeded with 4000 cells/ well of either breast cancer (MCF7) or normal fibroblast cells (F180) and incubated for 24 h at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. In a pilot experiment, metabolite extracts and AuNPs at concentrations 1, 10, 50, 100  $\mu$ g/ mL were suspended in mammalian cells media and filter sterilized using 0.22 filters prior to application on seeded cells. Only concentration 10  $\mu$ g/ mL was selected for further investigation based on the significant difference in activity obtained and according to previously published data [16]. The cultures were incubated for 16 h. A 200 $\mu$ L MTT (0.5mg/ mL) reagent was added to each well. The plates were incubated 2–4 h and the liquid was then discarded followed by addition of 200 $\mu$ L DMSO to each well. The endpoint of the experiment was indicated by the appearance of purple color. The color was measured using Multiskan Go machine (Spectrophotometer) at 570nm. Each experiment was done in duplicate, each with 6 repeats. Cell viability was calculated using the following formula adapted from [17] and according to our publication [14].

% of living cells = (OD experimental)/(OD control)  $\times$  100

#### Gas Chromatography-Mass Spectrometry (GC-MS)

GC-MS analysis was performed as described before [18]. The metabolite extracts were derivatized by adding 50  $\mu$ L of *N*-trimethylsilyl-*N*-methyl trifluoroacetamide and trimethylchlorosilane (MSTFA + 1% TMS) followed by incubation at 50 °C for 30 min prior to GC-MS analysis. The derivatized samples were injected into QP2010 gas chromatography-mass spectrometer (GC-2010 coupled with a GC-MS QP-2010 Ultra) equipped with an auto-sampler (AOC-20i+s) from Shimadzu (Tokyo, Japan), using Rtx-5ms column (30 m length × 0.25 mm inner diameter × 0.25  $\mu$ m film thickness; Restek, Bellefonte, PA). Data collection and analysis were performed using MSD Enhanced Chemstation software (Shimadzu). Product spectra were identified by comparison of the measured fragmentation patterns to those found in the NIST 08 Mass Spectral Library.

#### Statistical analysis

The data was collected and graphed using Graph Pad Prism (5.04, La Jolla, CA, USA). The effects of different extracts and AuNPs on cancer and fibroblast cell lines were analyzed by two-way analysis of variance (ANOVA). The statistical significance was calculated with Bonferroni's multiple comparisons test and significance level indicated by asterisks (\*, P<0.05; \*\*, P<0.01: \*\*\*, P<0.001; \*\*\*\*, P<0.0001). The data display the mean of the percentage of the survival rate of mammalian cells ± SEM of 6 replicas.

# Results

# Metabolites extracted from MCF7 cancer cells showed potential cytotoxic activities on their own

Cultures collected from mammalian cells either MCF7 or F180 were separated by centrifugation into cells and supernatant fractions. The metabolite extracts from both supernatants (SE1 and SE2) and cells (CE1 and CE2) fractions (<u>Table 1</u>) were tested individually on MCF7 and F180 cells. The results indicated that all suspended extracts showed significant but variable



**Fig 1. Cytotoxic activities of metabolites extracted from mammalian cell cultures.** (A) Cytotoxic activities of metabolites extracted from supernatants collected from F180 (SE1) and MCF7 (SE2) cell cultures. (B) Cytotoxic activities of metabolites extracted from F180 (CE1) and MCF7 (CE2) cells separated from mammalian cell cultures. The cells were seeded in 96-well plate at a concentration of  $5 \times 10^4$  cells/ well in 100 µl culture medium followed by incubation with the samples overnight prior to MTT assay. The data was analyzed using two-way ANOVA and statistical significance was calculated with Bonferroni's multiple comparisons test and significance level were indicated by asterisks (\*, *P*<0.05; \*\*, *P*<0.001; \*\*\*\*, *P*<0.0001). The data display the mean of the percentage of the survival rate of mammalian cells ± SEM of 6 replicas.

https://doi.org/10.1371/journal.pone.0240156.g001

cytotoxic activities when compared to control (Fig 1). Although extracts from both supernatants (SE1 and SE2) (Fig 1A) and fibroblasts cells (CE1) (Fig 1B) showed ~90% and 70% killing activities, respectively; this effect was non-selective as there was no significant difference in cell viability between MCF7 versus F180 cells. On the other hand, extracts from MCF7 cells (CE2) showed 95% versus 52% killing activities to MCF7 versus F180 cells, respectively (Fig 1B). The results obtained indicated that MCF7 cells metabolites extract (CE2) developed potential cytotoxic and safer activities. Metabolites extracted from MCF7 and F180 cells were analyzed by GC-MS and compared. The metabolites comparison showed the presence of many metabolites in MCF7 (CE2) but not F180 (CE1) (Fig 2). The biological activities of major metabolites identified from MCF7 but not from F180 were searched in the literature and summarized in Table 2. Most identified metabolites possess cytotoxic and oxidative catalytic activities. The results obtained indicate the importance of ligand-specific cells in targeting therapy.

# Gold nanoparticles (AuNPs) developed from metabolites extracted from MCF7 cells showed promising cytotoxic activities

Metabolites extracted from mammalian cells and mammalian cell-free supernatants were used separately to develop AuNPs using gold chloride. The AuNPs production was indicated by the change in the color of the solution to purple (U2 and U4) [12] compared to controls (Gold chloride in PBS: Cn and cells metabolites without Gold chloride: Cp) (Fig 3A). Careful micros-copy examination showed agglomerations of purple particles in wells containing metabolites-treated gold chloride (Fig 3B) while such agglomerations were absent in control groups (Fig 3C). The obtained NPs were collected by centrifugation and analyzed by UV spectroscopy at 200–900 nm range and transmission electron microscope (TEM). The synthesized AuNPs (AuNP2 and AuNP4) showed a strong peak at  $\lambda_{Max}$  550 nm (Fig 3D), while no peak with the

Metabolites	CE1	CE2	Continued		Continued				
1,12-Dodecanediol	0	0.084	Azelaic acid	0	0.084	L-Isoleucine	0	0.816	
1,4-Butanediol	0	0.12	Butanedioic acid	0.1834	0.276	L-Leucine	0	0.72	
1-Adamantane carboxylic			Butanoic acid	0.1048	0.048	I-Norvaline	0.0786	0	
acid, 2-methylphenyl ester	1.3231	0	Cholesterol	29.9466	21.78	I-Proline	0	0.024	
1-Hexadecanol	0	0.048	D-(-)-Fructopyranose	0	0.132	L Sorino	0.0524	0.024	
1-Hexanol	6.4845	3.384	D-(+)-Ribono-1,4-lactone	0	0.648		0.0524	0.384	
1-Monomyristin	0	0.168	D-(+)-Talofuranose	0.2096	0	L-Inreonine	0.1048	1.56	
1-Monooleoylglycerol	0	0.024	D-(+)-Turanose	0	0.144	L-Tyrosine	0	0.12	
1-Monopalmitin	0	10.212	D-Mannitol	0	0.084	L-Valine	0.0655	0.888	
1-Octadecanol	0.0917	0.108	Docosanol	0.0655	0.324	1-O-nonyl-Lyxitol	0	0.132	
2 2 4 Tribudrovubuturic ocid		0.13	Dodecanedioic acid	0	1.332	Malic acid	0.0655	0.132	
2,3,4-Trinydroxybutyric acid	0 0202	0.12	D-Psicofuranose	0	0.468	Maltose	0.221	0.072	
2-Acetoxyacetate	0.0393	0 100	D-Psicopyranose	0.1703	0	Methyl galactoside	0	0.072	
2-Ethoxyethanol	0.3275	0.192	D-Xylose	6.5762	0	Mathedansina	22.0204	0.072	
2-Keto-d-gluconic acid	0	0.204	Erythro-Pentonic acid	0	0.3	wietnylamine	22.9381	11.748	
2-Methyl-1,3-butanediol	0	0.168	Ethanimidic acid	0.1179	0.132	Myristic acid	0.1965	0.24	
2-Monostearin	0	0.264	Ethanolamine	0.6026	2.4	Nonanoic acid	0	0.072	
2-Palmitoylglycerol	0	0.432	Glucopyranose	4.5326	4.932	Palmitic Acid	0.9432	1.356	
3-Hydroxybutyric acid	0	0.024	Glyceric acid	0.1048	0.12	Pentadecanoic acid	0	0.06	
3-Pyridinol	0.1048	0.06	Glycerol monostearate	0	6.12	Phenylalanine	0	0.12	
4-Hydroxymethyl-3,3,4-			Glycolic acid	0.3406	0.156	Prost 13 en 1 oic acid	0	0.12	
trimethyl-1,2-dioxetane	0	0.024	Hexanedioic acid	0	0.048	Pilestinesid		0.12	
(Z)-9-Hexadecenoic acid	0.393	0	L-5-Oxoproline	0.7467	2.22	Ribonic acid	0.2096	0.072	
(E)-9-Octadecenoic acid	0.1834	0.228	Lactic Acid	7.0216	11.412	Scyllo-Inositol	0.5895	0.648	
Acetic acid	3.1964	0	L-Asparagine	0	0.096	Squalene	0	0.024	
Aminomalonic acid	0	0.192	L-Aspartic acid	0	0.18	Stearic acid	0.4454	0.78	
Arachidic acid	0	0.084	L-Glutamic acid	0	0.324	Suberic acid	0	0.024	

Fig 2. Heatmap comparing the Gas Chromatography-Mass Spectrometry (GC-MS) analysis of metabolites extracted from F180 cells (CE1) versus those extracted from MCF7 cells (CE2). The amount represented the relative percentage of a metabolite in relation to total areas of all detected metabolites in an extract. Metabolite average relative percentages of three independent replicas were displayed as colors ranging from red representing the lowest value to green for the highest value. The mammalian cells were incubated in T75 flasks until ~90% confluency, followed by centrifugation at 19000 RCF for 15 min prior to extraction by methanol with the aid of pestle.

https://doi.org/10.1371/journal.pone.0240156.g002

#### Table 2. Reported activities of major distinctive metabolites.

Metabolite	Reported activities	Reference
1,4-Butanediol	It has cytotoxic activity that induces alteration in the glucose metabolism causing mitochondrial dysfunction.	[19]
1-Monopalmitin	It has inhibitory activities on P-glycoprotein.	[20]
2-Keto-d-gluconic acid	It has a role in oxidative catalytic activities.	[21]
Azelaic acid	It shows anti-proliferative and cytotoxic effects on human cells.	[22]
Octacosane	It can induce apoptosis.	[23]
Phosphoric acid	It shows metal stabilizer activities.	[24]
D-(+)-ribono-1,4-lactone	It shows cytotoxic effects.	[25]
1-O-nonyl-lyxitol	Toxic effects.	[26]
Arachidic acid	It has oxidative stability activities.	[27]
D-(-)- fructopyranose	It has oxidative and genotoxic effects.	[28]
Suberic acid	It has oxidative activity and it is associated with mitochondrial damage.	[29]
Cyclotetradecane	Can be involved in biofabrication of metal nanoparticles.	[30]

https://doi.org/10.1371/journal.pone.0240156.t002



Fig 3. Biogenic synthesis of AuNPs and identification using UV-Vis spectroscopy. (A) Synthesis of AuNPs from mammalian cells metabolites (F180:U2 for AuNP1 and MCF7:U4 for AuNP2) versus AuNPs developed from metabolites extracted from cell-free supernatant (U1 for AuNP3 and U3 for AuNP4) and controls (Gold chloride in PBS: Cn and cells metabolites without Gold chloride: Cp). Gold chloride was incubated with metabolites extracts for 4–6 days at 37°C in 12-well plates until the development of purple color. (B and C) Light microscopy of (B) AuNPs aggregates (AuNP2) versus (C) control showed no NPs. Scale bar = 50  $\mu$ m. (D and E) UV-visible spectra of (D) synthesized AuNPs (AuNP2) versus (E) control. AuNPs showed a peak at  $\lambda_{max}$  550nm.

https://doi.org/10.1371/journal.pone.0240156.g003

control (Fig 3E), which is consistent with previously reported data for the UV absorbance of  $Au^{3+}$  element [31].

The XRD scan of the synthesized AuNPs showed a significant diffraction peak at 2θ angle: 38.1° corresponding to 111crystal plane of face-centered gold in the nanoparticles solution made from metabolites extracted from mammalian cells (AuNP2 and AuNP4), but not from metabolites solution extracted from cell-free supernatants or PBS solution, employed as control (Fig 4A). The formation of AuNPs was confirmed by the energy dispersive spectroscopy (EDS) (Fig 4B). The EDS profile showed a strong Au<sup>3+</sup> signal from the NPs solution made from the metabolites extracted from mammalian cells. Furthermore, the surface morphology





**Fig 4.** Characterization of AuNPs (AuNP2). (A) X-ray diffraction (XRD) patterns of the synthesized AuNPs. (B) SEM–EDS (energy dispersive spectroscopy) profile of the synthesized AuNPs. (C) TEM micrographs of AuNPs showed spherical-shaped particles. The samples of AuNPs were placed on standard carbon-coated copper grids (200-mesh) and air-dried for about 2h prior to measurement.

https://doi.org/10.1371/journal.pone.0240156.g004

and topography of AuNPs analyzed by TEM showed well-defined spherical shape particles (Fig 4C). Measuring the particle size of synthesized AuNPs showed that 95% of the particles were in the size range of 28–34 nm. The average size and size distribution of the AuNPs were  $30.4 \text{ nm} \pm 0.6$  and  $0.637 \pm 0.156$ , respectively. Surface charge measurements showed that the particles carried a negative charge of  $12.16 \pm 1.59$ . The large value for size distribution can be due to partial aggregation as a result of the low surface charge and repulsive forces between the particles.

The collected AuNPs were tested on fresh cancer (MCF7) and normal (fibroblasts) cells. Surprisingly, AuNPs developed from mammalian cells (AuNP1 and AuNP2) showed significant cytotoxic activities (Fig 5A), while those obtained from supernatants (AuNP3 and AuNP4) showed limited cytotoxic activities (Fig 5B). Furthermore, the AuNPs developed from MCF7 cells metabolites (AuNP2) showed significant difference in the killing effects between cancer (MCF7) versus normal (fibroblasts) cells (~52% versus 2%, *P*-value <0.001) when compared to the effects of AuNPs developed from fibroblast metabolites (AuNP1) (75% versus



### Effect of Gold Chloride

**Fig 5.** Cytotoxic activities of AuNPs developed from metabolites extracted from (A) mammalian cells (F180: AuNP1 and MCF7: AuNP2) versus (B) cells-free supernatants (AuNP3 and AuNP4) compared to (C) Gold Chloride effect. The cells were seeded in 96-well plate until confluency followed by incubation with the samples overnight prior to MTT assay. The data was analyzed using two-way ANOVA and statistical significance was calculated with Bonferroni's multiple comparisons test and significance levels were indicated by asterisks (\*, P < 0.05; \*\*, P < 0.01: \*\*\*, P < 0.001; \*\*\*\*, P < 0.001). The data display the mean of the percentage of the survival rate of mammalian cells ± SEM of 6 replicas.

https://doi.org/10.1371/journal.pone.0240156.g005

65%, *P*-value <0.001) (Fig 5A). The obtained results indicate that AuNPs developed from MCF7 cell metabolites (AuNP2) showed promising anticancer activities. On the other hand, gold chloride incubated with PBS (employed as negative control) failed to develop NPs, while it caused ~100% killing effects to both mammalian cells (Fig 5C).

#### Metabolomics analysis supports the prediction of responsive metabolites

**Metabolites involved in biogenic synthesis of NPs (initiator metabolites).** To identify the metabolites involved in the formation of AuNPs, the NPs solutions obtained from F180 and MCF7 cells extracts were centrifuged and the supernatants were extracted with ethyl

acetate (SNE1 and SNE2) prior to GC-MS analysis. The metabolites analyzed by GC-MS were compared to the parent metabolites extracted from both mammalian cells (employed as control, CE1 and CE2). The metabolites identified in the control but not in the AuNPs supernatants (SNE1 and SNE2) were selected and considered as NPs-initiator metabolites (reductants), since they were used up during the biogenic synthesis of NPs (Fig 6A).

The selected metabolites from CE1 and CE2 were compared to each other in order to execute the shared metabolites (Fig 6A and 6B). To ensure that the identified metabolites are only unique to the formation of AuNPs, the metabolites extracted from cell-free supernatants (SE1 and SE2) were compared to the shared ones selected from CE1 and CE2 (Fig 6B and 6C). Three metabolites were identified to be shared between all extracts (SE1 and SE2 versus CE1 and CE2) including oleic acid, levoglucosan, and 18-methyl-nonadecanol. On the other hand, the metabolites shared between CE1/CE2 and not found in SE1/SE2 were considered as initiator and included 1,2-benzenedicarboxylic acid, bis-(2-methylpropyl) ester, 1-octadecanol, 4,8,12,16-tet-ramethylheptadecan-4-olide, arachidic acid, hexanedioic acid, L-norvaline, N-(2-ethylhexyloxy-carbonyl)- decyl ester, myristic acid, N-isovalerylglycine, octadecane and pentadecanoic acid.

**Metabolites involved in capping the NP.** To identify the capping metabolites, the nanoparticles (AuNP1 and AuNP2) obtained from both cell types were precipitated by centrifugation, washed, dried and extracted by methanol with the aid of sonication for 15 min. The extracted metabolites (NE1 and NE2) were analyzed by GC-MS and compared to each other (Fig 7), where Fig 7A indicated the metabolites shared between both NE1 and NE2, and Fig 7B indicated the different metabolites. Shared metabolites included stearic acid, palmitic acid, lactic acid, heptadecanoic acid, benzoic acid, 9,12-octadecadienoic acid (Z,Z)-, 4-hydroxybutanoic acid and 3-aminoisobutyric acid (Fig 7A). On the other hand, cyclotetradecane, octacosane, and tetratetracontane were identified only from the NE2 generated from MCF7 metabolites, while 2-hexyl-1-decanol, cholesterol, L-5-oxoproline, myristic acid, nonadecanoic acid, and nonanoic acid were identified only from those developed from fibroblasts metabolites (NE1) (Fig 7B).

Metabolites involved in increasing the activities of NPs (activator metabolites). Because the NP (AuNP2) developed from MCF7 showed promising activities when compared to those developed from F180 (AuNP1), metabolites extract identified in Fig 7 was compared to metabolites extracted from the original cells (Fig 2). Metabolites including tetratetracontane, octacosane and cyclotetradecane were identified from AuNP2 but not from the original cells or AuNP1 (Fig 7). Furthermore, the biological activities of the metabolites extracted from both AuNP1 (NE1) and AuNP2 (NE2) were compared (Fig 8). The results obtained indicated that AuNP2 metabolites (NE2) showed significant difference in the cytotoxic activities on both cell types when compared to those extracted from AuNP1 (NE1), which showed similar activities on both cells. This is consistent with the results obtained from Figs <u>1B</u> and <u>5A</u>; suggesting the important role of tetratetracontane, octacosane and cyclotetradecane in the variation in the activities of AuNP2 developed from MCF7. Moreover, it offers a specific approach in therapeutic target delivery [12].

### Discussion

In this study, AuNPs were synthesized using mammalian cell metabolites. The generated nanoparticles showed variable cytotoxic activities, while those generated from MCF7 showed more promising anticancer activities against MCF7. The variable activities were attributed to the variation in the metabolites profiles of both mammalian cells under study and their supernatants.

The nanoparticles generated from metabolites extracted from MCF7 showed significant differences in the cytotoxic activities between both cancer and normal cells, while those generated

Α		В						С	
CE1 SNE1	CE2 SNE2	CE	1	CE2	SE1	SE2	7		
beta - Alanine, 3TMS derivative 1,2-Benzenedicarboxylic acid	(R)-3-Hydroxybutyric acid, 2 <sup>1</sup> 1,12-Dodecanediol, 2TMS o beta. Alanine, 3TMS derivati 1,2-Benzenedicatboxylic a	(2.2.Dimeth	45.12.12	beta Alapine 3TMS	beta -Alanine 3TM S	(R)-3-Hydraxy butyr	ic i		
1,1,1-Trifluoroheptadecen-2 one 1-Docosene	.betaD-Glucopyranoside, m 1,2-Dipalmitin, TMS derivat 1,2 Benz enedic abovylic acii 1,2-Ethandimine, N,N ditrif	alnha Hurt	muish	1 22-Docosanadiol 2	1.1.1.3.5.5.7.7.7-Nor	beta -Alanine, 3TM	15		
1,2-Ethendimine, N,N-ditrifluoro 1-Octacosanol, TMS derivative	1.2 Ethandimine, N.N ditritu 1.3 Dioxolane, 2 heptyl 4 o 1.3 Bistrimethylsilyloxy/pen 1.3 Propanediol, 2TMS der	beta Sitos	terol TM	1 2-Benzenedic arbox	1, 1, 1-Trifluoroheptade	beta -D-Glucopy ra	no	BetaAlanine, 3TMS deriva	1,2-Benzenedicarboxylic ac
1,3-Propanediol, 2TMS derivativ 1-Pertadecene, 2-methyl- 18-Methyl-nonadecanol, trimeth 1-Phenylethanol, TBDMS der	1,3-Prepanediol, 2TMS derive 1,4-Dioxan-2-ol, TMS derive 18-Methyl-nonadecanol, trim 1,7-di-iso propyinaphthalen	1.2-Benzen	edicarbo	1.3-Bis/trimethylsilylo	1,2-Ethandimine, N.M	1,3-Bis(trimethy Isil)	y lo	18-Methyl-nonadecanol, trir	18-Methyl-nonadecanol, trin
1-Docesene 1-Triacontanol, TMS derivative 1-Dodecanol, TMS derivative 2,3-Bis()trimethylsily()oxy()pro	18-Norabietane 14-Aza-10, 12-dioxatetracyd 1-Docosene 1-Butanol, TMS derivative	18-Methyl-r	onadeca	18-Methyl-nonadecan	18-Methyl-nonadecar	18-Methyl-nonadec	an	a bar the state of the state of the	I O I I THOUGH
1-Methyl-1-n-butyl-1-silacyclobu 2-Aminobenzoxazole, 2TMS ( 1-Monomyristin, 2TMS derketive 2-Butene-1,4-diol, (E)-, 2TMS	1-Dodecanol, TMS derivative 1-Docosene 1-Methyl-1-n-butyl-1-silacryck 1-Dodecanol, TMS derivativ	18-Norabiet	ane	1-Heptadecanol, TMS	1-Dodecanol, TMS de	18-Norabietane		1-Methyl-1-n-butyl-1-silacyd	1-Octadecanol, IMS derivat
1-Monopalmitin, 2TMS derivative 2-Butenedioic acid, (E)-, 2TM 1-Octacosanol, TMS derivative 2-Decen-1-ol, (E)-, TMS derivative	1-Monopalmitin, 2TMS derival 1-Monopalmitin, 2TMS deri 1-Octacosanol, TMS derivati 1-Octacosanol, TMS derival	1-Diftert-but	yl)silylox	1-Hexacosene	1-M ethyl-1-n-butyl-1+	1-M ethyl-1-n-butyl-		3-Dodecanol, TMS derivativ	4,8,12,16-Tetramethylhepta
1-Octadecanol, TMS derivative 2-Methylhexacosane 1-Phenylethand, TBDMS derivat2-Monostrepin, 2TMS derivate	1-Octadecanol, TMS derivatir 1-Octadecanol, TMS derivatir 1-Pentadecanol, TMS derivatir	1-Hexadeca	nol	1-Octadecanol, TMS	1-Monomyristin, 2TM	1-Octadecanesulph	ion	A tort Amylphonol TMS do	Amehidic acid TMS dorivati
1-Tetradecarel, TMS derivative 2-Palmitoy(pycercl, 2TMS de 2.5. Di last butic 6 Utimethyle in 2.9 acts motholds i landowshad	1-Phenethylamine, TMS deri 1-Pentamethyldisilyloxyoct 1-Triacontanol, TMS derivativ 1-Phenethylamine, TMS de	1-Methyl-1-	n-butyl-1-	s1-Pentadecanol, TMS	1-Octadecanol, TMS	2-Ethyl-3-trimethyls	uity	4-tert-Antylphenol, 1113 del	Alachidic acid, 1915 derivat
2-Aminoberzoxazole, 2TMS de 2-Propyl-1-pentanol, TMS der	2-Aminobenzoxazole, 21MS 1-Triacontanol, 1MS derival 2-Bromotetradecane 2-Aminobenzoxazole, 21M	1-Nonadece	ne	1-Tetracosanol, TMS	1-Tetradecanol, TM S	2-Undecene, 3-met	ny	Diethylene glycol, 2TMS de	Hexanedioic acid, 2TMS de
2-Butene-1,4-diol. (E)-, 2TMS d/3-Tetradecanol, TMS derivative	2-Butene-1,4-diol, (b)-, 21M32-Bromo dodecane 2-Butenedioic acid, (b)-, 21M2-Bromotetradecane	1-Octacosa	nol, TMS	1-Triacontanol, TMS of	2.5-Di-tert-buty1-4-((tr	3,6, 10-Trioxa-2, 11-	dis	Levoqlucosan 3TMS deriva	Levoquicosan 3TMS derivat
2-Methyl-1,3-butanedici, 2TMS 4-4/lucromethamphetamine	2-Ethyl 3-Immethylsityloxy(tht2-Butene-1,4-diol, (E)-, 21N 2-Monostearin, 21MS derivet 2-Butenedioic acid, (E)-, 21	1-Octadeca	nol, TMS	2,2,11,11-tetramethyl	2-Bromotetradecane	3-Dodecanol, TM S	de		
2-methyloctacosane 4-Hydroxybutanoic acid, 21M 2-Monasteain, 21MS derivative 5-Eicosene, (E)-	2 Propyl-1 pentanol, TMS de 2 Hexyldodecyl propionate	2-Hydroxyo	ctanoic a	d2-Butenoic acid, 3-me	2-M ethyl-1,3-outaned	4.8, 12, 10-Tetramet	a T	Octacosane	L-Norvaline, N-(2-ethylhexyl
2-Palmitoylglycerol, 2TMS derid5-Octadecere, (E)- 2-Propenoic acid, 2-{(trimethyls/Acetamide, N-(1-phenylethyl)-	2 Undecene, 3-methyl-, (2) 2 Methylletracisane 3,6,10 Trioxa 2,11 disiladode 2 Monosteanin, 2TMS deriv	2-Octyldecy 2.6 10 Trice	1 propion	2-Propyl-1-pentanol, 1	2-Propenoic acid 2-I	4-tert-Amy inhenol	TM	Oleic Acid, (Z)-, TMS derive	Myristic acid, TMS derivativ
2-Propyl-1-pentanol, TMS derivel Acetin, bis-1,3-trimethylsilyl e 2-Tridecanone Adipic acid, TMS derivative	3 Dodecanol, TMS derivative 2-Propyl-1 pertanol, TMS d 3 Dodecanol, TMS derivative 2-Propyl-1 pertanol, TMS d	3,6,10-1100 2 kb draw b	a-2,11-0	s 3-Dodecanol, TMS de	2-Tridecanone	5-Dodecenoic acid.	Ø	Drepanaia asid desul sate	N leavelendebusine OTMC d
3,8 dioxa-2,9 distadecan-5 one Behenic acid, TMS derivative 3-Aminoisobutyric acid, 3TMS dBenzeneproparoic acid, 3,5-b	4 (Trmethylsilycey) 3 penter 2 Undecenoic acid	4 8 12 16 T	stramath	6 6 Diath Iboctadaca	3.8-dioxa-2.9-disilade	5-M ethylthioadeno	sin	Propanoic acid, decyr ester	N-Isovaleryigiycine, 21WIS d
3-Dodecanol, TMS derivative Benzoic Acid, TMS derivative 4-(Trimethyla/span)-3-penten-2-Boric acid, 3TMS derivative	4 Hydroxybutanoic acid, 211 3-Hydroxybhenylacetic acia 4 Midle / Diseased TMP, et 2 Missioni 700, doi:et/co.	4-Methyl.3.	heatanol	7.Trimethylsibyloxy.7.	3-Dodecanol, TM S d	9-Eicosene, (E)-		Trimethylsilyl tricosanoate	Octadecane
4-Hydroxybutancic acid, 2TMS Butyl eicosyl ether 6-Methol 2-January TMS deire Conferentialingung der met	4-tert-Amylphenol, TMS deriv3-Tetradecanol, TMS deriva 5-Dedecercia acid. (7). TMS 4-(Temathdalkow)/3-pert	4-tert-Amvl	shenol. T	8-Hentadecene	4-(TrimethyIsily oxy)-3	9-Octadecen-1-ol. (	Z)-		Oleic Acid (7)- TMS derive
4-tert-Amylphend, TMS derivati Cyclopropanebutanoic acid, 2	6 Elicosene, (E): 4-Hydroxybutanoic acid, 21 6 Methodosocios, 1716 Elicosene, (E):	8.11.14-Eic	osatrieno	Acetic acid. 2.6.6-trin	4-tert-A mylphenol, TI	Benzenemethanam	sine		Ciele Acia, (2)-, INIO deliva
5-Octadecene, (E)- d-Erythrotetroluranose, tris-O-	5 Octadecene, (E) 5 Octadecene, (E) 9 Einnere (E) 5 11 Turnethylatindery	Arachidic a	id, TMS	Arachidic acid, TMS of	Arachidic acid, TMS	Benzoic acid, hept	y14		Pentadecanoic acid, TMS d
Addpic acid, TMS derivative Addpic acid, TMS derivative Docosanol, TMS derivative	9-Octadecen-1-ol, (Z)-, TMS-6-Dimethyl/trimethylalyliail Acetamide, N(1-phenylethyl 9-Octadeceneic acid, 6)-,	Behenic ac	d, TMS d	Bromosuccinic acid,	Behenyl chloride	Cholesterol, TMS d	leri		
Arachido acid, TMS derivative Dodecanoic acid, TMS derivat Arachidonic acid, TMS derivative D-Pinitol, pertakis(trimethylsi	Adipic acid, TMS derivative Acetamide, N-(1-phenylethy Arachidic acid, TMS derivative Adipic acid, TMS derivative	Benzoic ac	d, heptyl	Butanedioic acid, 2Th	Benzoic acid, 2-metr	Cyclonexane, (1, 1-	cini cita		
Behenic acid, TMS derivative Elicosane Behenyl chloride Ethanimidic acid, N-(trimethyl	Behenic acid, TMS derivative Arachidic acid, TMS derival Benzene, (1 isocyanatoethyl Behenic acid, TMS derivati	D-(+)-Ribon	0-1,4-lact	Cholesterol, TMS deri	Butanoic acid 3 4hi	Diethyl Phthalate			
Benzenepropanoic acid, 3,5-bis Ether, dodecyl isopropyl Benzoic acid, 2-methylpropyl erEthylene glycol, 211/KS derivat	Benzenemethanamine, .alph Benzamide, TMS derivative Benzenepropanoic acid, 3.5 Benzene, (1 isocyanatoeth	Dehydroabi	etic acid,	Decyl isopropyl ether	Carbonic acid, decyl	Diethylene glycol, 2	270		
Benzoic Acid, TMS derivative Formamide, TMS derivative Butanedioic acid, 2TMS derivatinGlycerol monostearate, 2TMS	Benzoic acid, heptyl ester Benzeneacetamide, TMS d Benzoic Acid, TMS derivative Benzeneacetic acid, TMS e	Dihydroxya	cetone, 2	Disiloxane, hexameth	Diethylene glycol, 21	Ethanol, 2-(octaded	:yle		
Butancic acid, 3,4-bis((trimethy Glycerol, 3TMS derivative Carbonic acid, decyl undecyl egHeptadecanenitrile	Boric acid, 3TMS derivative Benzonepropanoic acid, 3, Butanedioic acid, 2TMS den Benzoic Acid, TMS derivati	Disulfide, d	-tert-dod	Dodecanoic acid, TM	Disilathiane, hexame	Ethanolamine, 3TM	S		
Cyclopentasiloxane, decarrethe Reptadecanoic acid, glycerin Diethylene dyccil, 2TMS derived Reptadecanoic acid, TMS der	Cholesterol, TMS derivative Boric acid, 3TMS derivative Cyclohexane, (1,1-dimethylp Batanedioic acid, 2TMS de	Docosane,	5-butyl-	D-threo-Pentonic acid	Dodecane	Gly colic acid, 2TM:	S d		
Disilathiane, hexamethyl- Docusrol, TAS designities Processing discretate	Cyclopentas loxane, decame Carbonic acid, ally! hexade D-(+)-Ribono-1,4-lactone, 3TI Carbonic acid, eicosyl viny	Dodecanoic	acid, 14	Hexadecane, 2,6,11,1	D-threo-P entonic ack	Hexacosanoic acid	. 1		
Dodecane Hexanodioic acid, bis(2-ethyl) Dodecane acid, TMS dorivative screened tetrafeeral ether	Declanoic acid, TMS dervativ Cyclopentals rokane, declan Diethyl Phthalate Cyclopentylcarboxylic acid	Glycolic ac	d 2TMS	al evoquensan 3TMS	Erythro-Pentonic ack	Hex ane doic acid, a	210		
D-three Pentonic acid, 3-deoxy Lactic Acid, 27MS derivative Encourse	Decesanol, TMS derivative Docesanol, TMS derivative Docesanol, TMS derivative	Hexadecvit	isitrifluor	Levulinic acid. TMS d	Hentadecane 2.6.10	Hexanedoic acid, da	des des		
Erythro-Pertonic acid, 2-deoxy-L-Novaline, N-(2-ethylhexylox	Ethanimidic acid, N-trimethy D-three Pentonic acid, 3 de	Hexamethy	lene diac	L-Norvaline, N-(2-ethy	Heptadecane, 3-met	L-(+)-Threose, tris()	trim		
Ethylere glycol, 2TMS deniativ/Methanone, (1-hydrorycycloh	Ethansiamine, 3TMS derivative -3-Pentadecen-2-ol	Hexanedioi	acid, 21	Methylamine, 2TMS of	Hexadecane, 1,1-bis	Levoglucosan, 3TM	S		
Glycerol monostearate, 2TMS dN-Methyltifluoioacetamide, T	Formamide, TMS derivative Ethanimidic acid, N-8imet	Isopimaric a	icid, TMS	Myristic acid, TMS de	Hy dracry lic acid, 2Th	Levulinic acid, TMS			
Heptacosane Octadecane, 5-methyl-	Giycerol, 3TMS deniative Giycerol, artid, 2TMS deniative Giycerol, artid, 2TMS deniative Giycerol, artid, 2TMS deniative Giycerol, 3TMS deniative	Levoglucos	an, 3TMS	N(2).N(2)-Dimethyl-1.2	Ibuprofen, TMS deriva	Malonic acid, 2-hep	pt y		
Heptadecane, 2,6,10,15-tetramPalmitic Acid, TMS derivative Heptadecane, 3-methyl- Pentadecane	Heptadecane, 2,6,10,15-tetra Glycerol, 3TMS derivative	Lignoceric a	icid, TMS	N-Isovalerylglycine, 2	Levoglucosan, 3TM S	N-(. alphaMethylbo	HT2		
Heptadecandic acid, glycetine-IPentadecandic acid, glycerine Heptadecandic acid, TMS derivePherel, 2,4-bis(1,1-dimethyle	Heptadecanoic acid, TMS de Heptadecane, 2.6.10,15 tel Hexacosanoic acid, TMS de Heptadecaneritrile	Linolool axi	de, TMS	Octadecane	Mercaptoacetic acid.	Nicotinamide N-oxi	de,		
Hexadecane, 1,1-bis(dodecytox Propionic acid, 3-iodo-, hepta Hexamethylene diacrylate Steatic acid, TMS derivative	Hexamethylene diacrylate Heptadecanoic acid, glyce Hexanedioic acid, 2TMS der Heptadecanoic acid, TMS e	L-Norvaline,	N-(2-eth	Octadecane-1,12-diol	Methcathinone	Nonadecane, 1-cris	ora		
Hydracrylic acid, 2TMS derivativ Trimethylsilyl 22-(trimethylsily buprolen, TMS derivative Trisiloxane, 1,1,1,5,5,5-hexan	Nexanedioic acid, dioctyl es Nexamethylene diacrylate Nexanoic acid, 4-tetradecyl eNexanedioic acid, bis(2-eth	Methyl 8-m	ethyl-dec	a Octanoic acid, 4-meth	Metholyacetic acid, Methylamine 2TMS	Octadecane			
Lactic Acid, 2TMS derivative 0 Levoaluceaan, 3TMS derivative 0	Hippuric acid, TMS derivative Hippuric acid, TMS derivati Hydracrylic acid, 2TMS deriv Hydracrylic acid, 2TMS der	Myristic ac	d, IMS d	Oleamide, TMS derva	Myo-Inositol, 6TMS (	Oleic Acid. (Z). TM	15		
Levelinic acid, TMS deniative 0 L-Noneline, N-octvlowcarbony 0	L (+) Threose, tris(trimethyls isobutyl pent-4-enyl carbon Lactic Acid, 2TMS derivative Lactic Acid, 2TMS derivativ	Octocorpo	gycine, i	Destadacana	Myristic acid, TMS d	Phenyl tert-butyl ke	ito		
Mercaptoacetic acid, 2TMS der 0	Levoglucosan, 3TMS derivati/Linolool oxide, TMS derivat Levulinic acid, TMS derivativeL.Nonaline, N-octy/exycart	Octadecan		Pentadecanoic acid	N-Isovalerylglycine, 2	Propanoic acid, de	cyl		
Methodhinone 0 Methodusetic acid Abayatar	L-Nonaline, Noctyloxycarbo L-Nonaline, Noctyloxycarb Malonic acid, 2-heptyl tetrad Mandelic acid, 2TMS deriv	Octadecan	2-meth	Propanoic acid, decv	Nonacosane, 3-meth	Tetradecane, 2,6,1	0-6		
Methylamine, 2TMS derivative 0	Methanone, (1-hydroxycyclo Mercaptoethanol, 21MS de Myristic acid, TMS dervative Methanone, (1-hydroxycyc	Oleic Acid.	(Z)-, TMS	R(+)-Methcathinone	Octacosane	Thiourea, diethy lan	sin		
Myristic acid, TMS derivative 0	N-(aiphaMethylberzy()-form Mynetic acid, TMS deriveth N-(Hydroxymethyl)trifluoroac N-(Hydroxymethyl(trifluoroa	Palmitelaid	c acid, T	Silanamine, N,N-meth	Octadecane, 2-meth	Tridecane, 3-cy clot	160		
N-kowlerylglycire, 2TMS deriv	N Methyltrifuoroacietamide, Nonadecane	Pentadecar	oic acid,	Silanol, trimethyl-, ph	Octadecane-1, 12-dio	Trimethylsityl octac	08		
Nonacosane, 3-methyl- 0	Nonancic acid, TMS derivativ Octadecanal	Propionic a	cid, 3-iod	Tetradecanoic acid, 1	Ovalic acid isobutyl	Undecaroic acid 1	1.4		
Nonanoic acid, TMS derivative 0 Octacosane 0	Octadecane Oxalic acid, decyl 3,5 diffu Octadecane Divalic acid, decyl 3,5 diffu	Silanamine	N/N-me	Trifluoroacetamide, 21	Propanoic acid, decy		0		
Octadecane, 2-methyl- 0 Octadecane-1,12 diol bis(trimet 0	Oleic Acid, (2), TMS derivets Pentadecane Relation Acid, TMS derivets Pantadecane	Silane, [(11	-chloroun	Trisiloxane, 1,1,1,5,5,	Propionic acid, 3-lod		0		
Okic Acid, (2)-, TMS derivative 0 Oxalic acid, isobutyl undecyl es 0	Pentadecane Pentane, 2,2,3,3-tetrameth Pentadecanoic acid, olyceric Phenol, 2,4 biell, 1 dimeth	Silanol, trin	ethyl-, p	Undecanoic acid, 11-	Pyrimidine, 5-methyl		0		
Patritic Acid, TMS derivative 0 Pontadecane 0	Phenol, 2,4-bis(1,1 dimethyle Propyl letradecyl cabonate Phenyl tert butyl ketone Pyrimidine, 5-methyl 2,4 bi	Tetratetraco	ntane	Urea, 2TMS derivative	Silanamine, N.N'-met	1	0		
Pentadecandic acid, glycetine-0 Propanoic acid, decvi ester co	Propanoic acid, decyl ester R(+) Methcathinone Pyrimidine, 5 methyl-2,4 bis Silanamine, N.N. methanet	Iniourea, di	eolytami	0	Silanol, trimethyl-, ph	1	0		
Propionic acid, 3-iodo-, octadeo 0 Pwimidine, 5-methyl-2,4-bis/ite	Silanamine, N.N.methanetet Stearic acid, TMS derivative Stearic acid, TMS derivative Terpin, 2TMS derivative	Trimetade	ul tricore	0	Tetradecane, 5-meth	1	0		
Stanamine, N,N-methanetetray Stand trimethyl, chrosobate (	Sulturous acid, 2 ethylhexyl Topin, 2TMS dervetive Trislicxane, 1,1,1,5,5-hex	Trivindhud	novmeth		Trimethyle by trices		0		
Stearic acid, TMS defeative 0	Tetradecane, 2,6,10-trimethy Uracil, 2TMS derivative Thicurea, diethylaminomethy 0	Undecanal			Uracil 13-histrimat		0		
Tetrasiloxane, decamethyl-	Tridecane, 3-cyclohexyl- Trimethylsilyl 22-(himethylsil) 0	Z-10-Methy	-11-tetra	d 0	Urea, 2TMS derivative		0		
Trimethylaityl tricosanoate o	Trimethylsityl octacosanoate 0 Trimethylsityl tricosanoate 0								
Uma, 7,3-us(trimetry(sig)) 0	Undecanoic acid, 11 fluoro, 0 Uracii, 27MS denetive								

**Fig 6. Identification of metabolites involved in biogenesis of AuNPs using GC-MS analysis.** Metabolites (SNE1 and SNE2) extracted from the solution obtained after the generation of AuNPs were compared to the parent metabolites extracts (CE1 and CE2) used for their generation. The metabolite difference in the parent metabolites were selected and re-compared to metabolites extracted from cell-free supernatants (ES1 and ES3). Gold chloride was incubated with metabolites extracts dissolved in PBS for 4–6 days until the color changes. The cultures were spin down and the supernatant was collected. The supernatant was re-extracted with ethyl acetate prior to GC-MS analysis. The results obtained were compared with control extracts treated similarly but without gold chloride. (A) Metabolites comparison between gold chloride-treated versus non-treated samples. Light red-colored metabolites are shared metabolites between samples, while the uncolored metabolites extracted from supernatants (SE1 and SE2). Light red-colored metabolites between samples are different. (C) Only shared metabolites were combined from supernatants versus cells. Light red-colored metabolites between samples, while the orange metabolites are different.

https://doi.org/10.1371/journal.pone.0240156.g006

from F180 or cells-free supernatants did not. It has been reported that AuNPs demonstrated different cytotoxic effects on different mammalian cells [32]. Although the variable cytotoxic activities on different mammalian cells have been attributed to the size and level of aggregations [8], our results showed that the origin of reductants is another factor. The metabolites extracted from MCF7 cells caused significant anticancer activities on MCF7 when compared to F180, while those extracted from F180 cells showed no differences in cytotoxic activities on both cell types. Similarly, AuNPs generated from MCF7 caused variable activities on both cell types, while those generated from F180 are not. We attributed this difference in activities to

Metabolites Extracted from									Δ
MCF7	F180	AuNP							
0.8 ± 0.03	0.5 ± 0.05	Stearic acid							
$1.4\pm0.04$	$0.9 \pm 0.4$	Palmitic Acid						3	
$11.4\pm0.12$	7.0±0.04	Lactic Acid							
0	0	Heptadecanoic acid						NE1	
0	0	Benzoic Acid						NE2	
0	0	9,12-Octadecadienoic acid (Z,Z)-	-						
0	0	4-Hydroxybutanoic acid	1						
0	0	3-Aminoisobutyric acid	<u> </u>						
		-1	0	1		2	3	4	5
0	0	Tetratetracontane		BH					
0	0	Octacosane	-						R
0	0	Cyclotetradecane	-						D
0.1±0.02	0	Nonanoic acid	⊐						
0	0	Nonadecanoic acid	$\square$						
0.2±0.04	0.2±0.06	Myristic acid	<b></b> BH						
2.2±0.02	0.7±0.05	L-5-Oxoproline	<b></b> 84						
21.7±0.08	29.9±0.4	Cholesterol	ň						
$0.5\pm0.04$	0	2-hexyl-1-Decanol	<u> </u>			<b></b>			
			0	0.5	1	1.5			

**Fig 7. Identification of AuNPs-capping metabolites.** NPs solution was centrifuged and the NPs were collected and washed by PBS two times prior to extraction using methanol and sonication for 15 min. The extracted metabolites were analyzed by GC-MS and compared to those extracted from NP-free supernatants. (A) Metabolites were identified from NPs and shared between F180 and MCF7 cell lines. (B) Unique metabolites identified from NPs developed from MCF7 versus those developed from F180. The data display the mean of the percentage of the metabolites  $\pm$  SEM of three replicas. The table on the left represented the comparison between the identified metabolites from NPs to those identified in Figs 2 and 6.

https://doi.org/10.1371/journal.pone.0240156.g007

the presence of variable metabolites species or levels. Many different bio-molecular chemicals were reported to be involved in AuNPs formation and stabilization into smaller nanoclusters. These chemicals include amino acids, protein side chains, glutathione, phospholipids, and many more [6].

Metabolites that may cap or conjugate to NPs were extracted and showed that some metabolites identified only from AuNPs generated from MCF7 including tatratetracontane, octacosane and cyclotetradecane, while other metabolites were related to F180 including hexyldecanol, oxoproline, myristic acid and nonanoic acid. Saturated hydrocarbons such as octacosane have been reported to induce apoptosis [23]. On the other hand, fatty acids level were 10–20 times higher in case of NPs generated from F180 when compared to those identified from AuNPs generated from MCF7. The presence of a high level of fatty acids may be responsible for the higher non-selective cytotoxic activities of AuNPs generated from F180.



**Fig 8. Cytotoxic activities of metabolites extracted from AuNPs.** NPs solution was centrifuged and the NPs were collected and washed by PBS two times prior to extraction using methanol and sonication for 15 min. The extracted metabolites were tested on F180 and MCF7 cells using MTT assay. Mammalian cells were seeded in 96-well plate until confluency followed by incubation with the samples overnight prior to MTT assay. The data were analyzed using two-way ANOVA and statistical significance was calculated with Bonferroni's multiple comparisons test and significance levels were indicated by asterisks (\*, P < 0.05; \*\*, P < 0.01; \*\*\*\*, P < 0.001). The data display the mean of the percentage of the survival rate of mammalian cells  $\pm$  SEM of 5 replicas.

https://doi.org/10.1371/journal.pone.0240156.g008

Consistently, the cytotoxicity due to free fatty acids was reported [33]. Although few metabolites with cytotoxic activities were identified from MCF7 but not from F180, none of them was detected from AuNPs themselves. These metabolites included azelaic acid [34], D-(+)-ribono-1,4-lactone [25], 1-O-nonyl-lyxitol [26] and phosphoric acid [35].

The metabolites predicted from mammalian cells and involved in biogenic synthesis of AuNPs were mainly alcohols and acids. These metabolites included 1,2-benzenedicarboxylic acid, bis(2-methylpropyl) ester, octadecanol, arachidic acid, hexanedioic acid, myristic acid and pentadecanoic acid. For example, 1,2-benzenedicarboxylic acid, bis(2-methylpropyl) ester is a reducing agent [36]. On the other hand, oleic acid has been identified in all metabolites extracts. Oleic acid can modify the electronic structure of AuNPs [37], stabilize AuNPs [38] and affect the cytotoxic activities of AuNPs [39] but cannot initiate the synthesis of NPs.

The use of plant metabolites [40] or bacterial metabolites [41] to induce the reduction of gold to nanoparticles has been reported before. However, the use of mammalian cell metabolites to generate gold nanoparticles is the first. The results obtained in this study may help to design a well-controlled delivery system after optimization of size and aggregation level using fractional size exclusion chromatography. Furthermore, optimization of the metabolites capping the nanoparticles will be of important value to identify the metabolites with significant impact on the developed nanoparticles. Although the focus of this manuscript was the breast cancer cells (MCF7), we believe that further future investigations are required. Testing the biological activities of NPs developed from metabolites extracted from different breast cancer fractions such as the cell membrane and cytosol will help to narrow down the metabolites responsible for the variable activities. Repeating the NPs synthesis using different cancer cells

will help to either generalize or specify our final conclusion. Moreover, fractionation of the extracted metabolites used to develop the nanoparticles by column chromatography or HPLC followed by NPs synthesis and activities will also help to identify the major responsive metabolites.

# Conclusions

In conclusion, it has been demonstrated that metabolites extracted from mammalian cells are capable of producing AuNPs extracellularly and the generated nanoparticles are quite stable. The developed nanoparticles showed variable cytotoxic activities depend on the used cell types. Nanoparticles generated from MCF7 metabolites showed promising anticancer activities on their own. This variation in anticancer activities was attributed to the differences in the metabolites and/ or their levels. This report will also lead to the development of a rational bio-synthetic procedure from other mammalian cells or their compartments for several and unique biomedical applications.

# **Author Contributions**

Conceptualization: Sameh S. M. Soliman.

Data curation: Sameh S. M. Soliman.

Formal analysis: Sameh S. M. Soliman.

Funding acquisition: Sameh S. M. Soliman.

- **Investigation:** Sameh S. M. Soliman, Tasneem B. Alhamidi, Shifaa Abdin, Ahmed M. Almehdi, Razan B. Alhumaidi, Sarra B. Shakartalla, Mohamed Haider, Mohamed I. Husseiny, Hany A. Omar.
- Methodology: Sameh S. M. Soliman, Tasneem B. Alhamidi, Shifaa Abdin, Ahmed M. Almehdi, Mohammad H. Semreen, Razan B. Alhumaidi, Sarra B. Shakartalla, Mohamed Haider, Mohamed I. Husseiny, Hany A. Omar.
- Resources: Mohamed Haider, Mohamed I. Husseiny, Hany A. Omar.

Supervision: Sameh S. M. Soliman.

Validation: Sameh S. M. Soliman.

Visualization: Sameh S. M. Soliman.

Writing – original draft: Sameh S. M. Soliman, Ahmed M. Almehdi, Mohammad H. Semreen, Mohamed Haider, Mohamed I. Husseiny, Hany A. Omar.

Writing - review & editing: Sameh S. M. Soliman, Tasneem B. Alhamidi.

### References

- Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: Recent advances and perspectives. Chem Soc Rev. 2012; 41(6):2256–82. https://doi.org/10.1039/c1cs15166e PMID: 22130549
- Freitas de Freitas L, Varca GHC, Dos Santos Batista JG, Benévolo Lugão A. An overview of the synthesis of gold nanoparticles using radiation technologies. Nanomaterials (Basel). 2018; 8(11):939. <a href="https://doi.org/10.3390/nano8110939">https://doi.org/10.3390/nano8110939</a> PMID: 30445694
- He S, Guo Z, Zhang Y, Zhang S, Wang J, Gu N. Biosynthesis of gold nanoparticles using the bacteria *Rhodopseudomonas capsulata*. Mater Lett. 2007; 61(18):3984–7. https://doi.org/10.1016/j.matlet. 2007.01.018.

- Lengke MF, Fleet ME, Southam G. Morphology of gold nanoparticles synthesized by filamentous cyanobacteria from gold(i)-thiosulfate and gold(iii)-chloride complexes. Langmuir. 2006; 22(6):2780–7. https://doi.org/10.1021/la052652c PMID: 16519482
- Husseiny MI, El-Aziz MA, Badr Y, Mahmoud MA. Biosynthesis of gold nanoparticles using *Pseudomo-nas aeruginosa*. Spectrochim Acta A. 2007; 67(3):1003–6. https://doi.org/10.1016/j.saa.2006.09.028.
- Drescher D, Traub H, Büchner T, Jakubowski N, Kneipp J. Properties of in situ generated gold nanoparticles in the cellular context. Nanoscale. 2017; 9(32):11647–56. <u>https://doi.org/10.1039/c7nr04620k</u> PMID: 28770918
- Cui W, Li J, Zhang Y, Rong H, Lu W, Jiang L. Effects of aggregation and the surface properties of gold nanoparticles on cytotoxicity and cell growth. Nanomedicine. 2012; 8(1):46–53. <u>https://doi.org/10.1016/j.nano.2011.05.005</u> PMID: 21658475
- Coradeghini R, Gioria S, García CP, Nativo P, Franchini F, Gilliland D, et al. Size-dependent toxicity and cell interaction mechanisms of gold nanoparticles on mouse fibroblasts. Toxicol Lett. 2013; 217 (3):205–16. https://doi.org/10.1016/j.toxlet.2012.11.022 PMID: 23246733
- Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers (Basel). 2019; 11(5):640. <u>https://doi.org/10.3390/cancers11050640</u> PMID: 31072061.
- Wu J-J, Omar HA, Lee Y-R, Teng Y-N, Chen P-S, Chen Y-C, et al. 6-Shogaol induces cell cycle arrest and apoptosis in human hepatoma cells through pleiotropic mechanisms. European Journal of Pharmacology. 2015; 762:449–58. https://doi.org/10.1016/j.ejphar.2015.06.032 PMID: 26101062
- Soliman S, Li XZ, Shao S, Behar M, Svircev AM, Tsao R, et al. Potential mycotoxin contamination risks of apple products associated with fungal flora of apple core. Food Control. 2015; 47:585–91. https://doi. org/10.1016/j.foodcont.2014.07.060.
- Yeh Y-C, Creran B, Rotello VM. Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale. 2012; 4(6):1871–80. Epub 2011/11/10. https://doi.org/10.1039/c1nr11188d PMID: 22076024.
- Al-Nuairi AG, Mosa KA, Mohammad MG, El-Keblawy A, Soliman S, Alawadhi H. Biosynthesis, characterization, and evaluation of the cytotoxic effects of biologically synthesized silver nanoparticles from *Cyperus conglomeratus* root extracts on breast cancer cell line MCF-7. Biol Trace Elem Res. 2019:1– 10.
- Hamdy R, Fayed B, Hamoda AM, Rawas-Qalaji M, Haider M, Soliman SSM. Essential Oil-Based Design and Development of Novel Anti-Candida Azoles Formulation. Molecules (Basel, Switzerland). 2020; 25(6):1463. https://doi.org/10.3390/molecules25061463 PMID: 32213931.
- Soliman S, Hamoda AM, El-Shorbagi A-NA, El-Keblawy AA. Novel betulin derivative is responsible for the anticancer folk use of *Ziziphus spina-christi* from the hot environmental habitat of UAE. J Ethnopharmacol. 2019; 231:403–8. https://doi.org/10.1016/j.jep.2018.11.040 PMID: 30508621
- Sun H, Jia J, Jiang C, Zhai S. Gold Nanoparticle-Induced Cell Death and Potential Applications in Nanomedicine. Int J Mol Sci. 2018; 19(3):754. https://doi.org/10.3390/ijms19030754 PMID: 29518914.
- 17. Khatibi S, Taban ZF, Roushandeh AM. In vitro evaluation of cytotoxic and antiproliferative effects of *Portulaca oleracea* ethanolic extracton on hela cell line. Gene Cell Tissue. 2016; 4(1):e13301.
- Semreen MH, Soliman SSM, Saeed BQ, Alqarihi A, Uppuluri P, Ibrahim AS. Metabolic profiling of candida auris, a newly-emerging multi-drug resistant candida species, by GC-MS. Molecules. 2019; 24 (3):399. https://doi.org/10.3390/molecules24030399 PMID: 30678308
- Nocca G, Martorana GE, De Sole P, De Palma F, Callà C, Corsale P, et al. Effects of 1, 4-butanediol dimethacrylate and urethane dimethacrylate on HL-60 cell metabolism. Eur J Oral Sci. 2009; 117 (2):175–81. https://doi.org/10.1111/j.1600-0722.2008.00606.x PMID: 19320727
- Konishi T, Satsu H, Hatsugai Y, Aizawa K, Inakuma T, Nagata S, et al. Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. Br J Pharmacol. 2004; 143(3):379–87. Epub 2004/09/06. https://doi.org/10.1038/sj.bjp.0705804 PMID: 15351776.
- Zeng W, Cai W, Liu L, Du G, Chen J, Zhou J. Efficient biosynthesis of 2-keto-D-gluconic acid by fedbatch culture of metabolically engineered *Gluconobacter japonicus*. Synth Syst Biotechnol. 2019; 4 (3):134–41. https://doi.org/10.1016/j.synbio.2019.07.001 PMID: 31384676
- 22. Fitton A, Goa KL. Azelaic acid. Drugs. 1991; 41(5):780–98. <u>https://doi.org/10.2165/00003495-199141050-00007 PMID</u>: 1712709
- Figueiredo CR, Matsuo AL, Pereira FV, Rabaça AN, Farias CF, Girola N, et al. Pyrostegia venusta heptane extract containing saturated aliphatic hydrocarbons induces apoptosis on B16F10-Nex2 melanoma cells and displays antitumor activity in vivo. Pharmacogn Mag. 2014; 10(Suppl 2):S363–S76. https://doi.org/10.4103/0973-1296.133284 PMID: 24991116.

- 24. Kim N-H, Lim J-H, Kim S-Y, Chang E-G. Effects of phosphoric acid stabilizer on copper and tantalum nitride CMP. Mater Lett. 2003; 57(29):4601–4. https://doi.org/10.1016/S0167-577X(03)00368-9.
- Kitajima J, Ishikawa T, Tanaka T, Ida Y. Water-soluble constitutents of fennel. IX. glucides and nucleosides. Chem Pharm Bull. 1999; 47(7):988–92. https://doi.org/10.1248/cpb.47.988
- **26.** Gan W, Zhou M, Xiang Z, Han X, Li D. Combined effects of nonylphenol and bisphenol a on the human prostate epithelial cell line RWPE-1. Int J Environ Res Public Health. 2015; 12(4):4141–55. <u>https://doi.org/10.3390/ijerph120404141</u> PMID: 25874684.
- Araseki M, Yamamoto K, Miyashita K. Oxidative stability of polyunsaturated fatty acid in phosphatidylcholine liposomes. Biosci Biotechnol Biochem. 2002; 66(12):2573–7. https://doi.org/10.1271/bbb.66. 2573 PMID: 12596850
- Czubatka-Bienkowska A, Macieja A, Sarnik J, Witczak ZJ, Poplawski T. The oxidative induction of DNA lesions in cancer cells by 5-thio-d-glucose and 6-thio-d-fructopyranose and their genotoxic effects. Part 3. Bioorg Med Chem Lett. 2017; 27(5):1210–4. <u>https://doi.org/10.1016/j.bmcl.2017.01.011</u> PMID: 28094181
- Largilliere C, Vianey-Saban C, Fontaine M, Bertrand C, Kacet N, Farriaux J-P. Mitochondrial very long chain acyl-CoA dehydrogenase deficiency-a new disorder of fatty acid oxidation. Arch Dis Child. 1995; 73(2):F103–F5.
- Jayaseelan C, Gandhi PR, Rajasree SRR, Suman TY, Mary RR. Toxicity studies of nanofabricated palladium against filariasis and malaria vectors. Environ Sci Pollut Res. 2018; 25(1):324–32. <u>https://doi.org/10.1007/s11356-017-0428-x PMID: 29034429</u>
- Shang Y, Min C, Hu J, Wang T, Liu H, Hu Y. Synthesis of gold nanoparticles by reduction of HAuCl4 under UV irradiation. Solid State Sci. 2013; 15:17–23. https://doi.org/10.1016/j.solidstatesciences. 2012.09.002.
- Chueh PJ, Liang R-Y, Lee Y-H, Zeng Z-M, Chuang S-M. Differential cytotoxic effects of gold nanoparticles in different mammalian cell lines. J Hazard Mater. 2014; 264:303–12. <u>https://doi.org/10.1016/j.jhazmat.2013.11.031</u> PMID: 24316248
- Siegel I, Liu TL, Yaghoubzadeh E, Keskey TS, Gleicher N. Cytotoxic effects of free fatty acids on ascites tumor cells2. JNCI. 1987; 78(2):271–7. https://doi.org/10.1093/jnci/78.2.271 PMID: 3468290
- N Z, R V, L S, O S, R S. Cytotoxic activity of azelaic acid against human melanoma primary cultures and established cell lines. Anticancer Res. 1990; 10(6):1599–602. PMID: 2285231
- Prado M, Silva EJNLd, Duque TM, Zaia AA, Ferraz CCR, Almeida JFAd, et al. Antimicrobial and cytotoxic effects of phosphoric acid solution compared to other root canal irrigants. J Appl Oral Sci. 2015; 23:158–63. https://doi.org/10.1590/1678-775720130691 PMID: 26018307
- Ghosh S, Derle A, Ahire M, More P, Jagtap S, Phadatare SD, et al. Phytochemical analysis and free radical scavenging activity of medicinal plants *Gnidia glauca* and *Dioscorea bulbifera*. PLoS One. 2013; 8(12):e82529–e. https://doi.org/10.1371/journal.pone.0082529 PMID: 24367520.
- de la Presa P, Multigner M, de la Venta J, García MA, Ruiz-González ML. Structural and magnetic characterization of oleic acid and oleylamine-capped gold nanoparticles. J Appl Phys. 2006; 100 (12):123915. https://doi.org/10.1063/1.2401314
- Sadrolhosseini AR, Abdul Rashid S, Zakaria A. Synthesis of gold nanoparticles dispersed in palm oil using laser ablation technique. J Nanomater. 2017; 2017:5. https://doi.org/10.1155/2017/6496390
- Poursharifi M, Wlodarczyk MT, Mieszawska AJ. Nano-based systems and biomacromolecules as carriers for metallodrugs in anticancer therapy. Inorganics. 2018; 7(1):2. <u>https://doi.org/10.3390/inorganics7010002</u>
- Kasthuri J, Veerapandian S, Rajendiran N. Biological synthesis of silver and gold nanoparticles using apiin as reducing agent. Colloids Surf B Biointerfaces. 2009; 68(1):55–60. <u>https://doi.org/10.1016/j.</u> colsurfb.2008.09.021 PMID: 18977643
- Rajeshkumar S. Anticancer activity of eco-friendly gold nanoparticles against lung and liver cancer cells. J Genet Eng Biotech. 2016; 14(1):195–202. https://doi.org/10.1016/j.jgeb.2016.05.007.